European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag - icatibant - angioedemas, hereditary - cardiac therapy - firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults (with c1-esterase-inhibitor deficiency).

Canada - English - Health Canada

takeda canada inc - icatibant (icatibant acetate) - solution - 10mg - icatibant (icatibant acetate) 10mg - complement inhibitors

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, hereditary - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Malta - English - Medicines Authority

adalvo limited malta life sciences park, building 1, level 4 sir temi zammit san gwann industrial est, sgn 3000 san gwann, malta - icatibant - solution for injection in a pre-filled syringe - icatibant 10 mg/ml - other hematological agents

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - icatibant acetate - solution for injection in pre-filled syringe - icatibant

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - icatibant acetate - solution for injection in pre-filled syringe - icatibant

Canada - English - Health Canada

teva canada limited - icatibant (icatibant acetate) - solution - 10mg - icatibant (icatibant acetate) 10mg

Canada - English - Health Canada

juno pharmaceuticals corp. - icatibant (icatibant acetate) - solution - 10mg - icatibant (icatibant acetate) 10mg

Canada - English - Health Canada

accord healthcare inc - icatibant (icatibant acetate) - solution - 30mg - icatibant (icatibant acetate) 30mg

Israel - English - Ministry of Health

teva israel ltd - icatibant as acetate - solution for injection - icatibant as acetate 30 mg / 3 ml - icatibant - icatibant teva is indicated for symptomatic treatment of acute attacks of hereditary angioedima (hae) in adults, adolescents and children aged 2 years and older, with c1-esterase-inhibitor deficiency.